UFP Technologies NASDAQ: UFPT outlined its strategy to expand through organic growth and acquisitions, emphasizing its role as a contract development and manufacturing organization serving medical-device companies.
UFP Industries, Inc. is rated Hold due to valuation concerns despite recent price declines and operational challenges. UFPI's revenue and profitability have suffered from weak demand, lower selling prices, and rising freight costs, with only modest recent improvement. The Retail segment remains the most resilient and profitable, while Packaging and Construction segments face margin pressure and operational inefficiencies.
UFP Technologies NASDAQ: UFPT reported second-quarter 2026 sales growth of 15.1% to $174 million, supported by broad-based demand across its medical technology portfolio, while adjusted earnings per share rose 16.8% to a company-record $2.92.
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mitchell C. Rock CEO | XFRA Exchange | 902673102 CUSIP |
| US Country | 4,846 Employees | - Last Dividend | - Last Split | 16 Dec 1993 IPO Date |
UFP Technologies, Inc. is a company specializing in the design and custom manufacturing of components, subassemblies, products, and packaging using specialized foams, films, and plastics with a primary focus on the medical market. Since its inception in 1963, the company has expanded its offerings to meet the needs of several other sectors, including automotive, aerospace and defense, consumer electronics, and industrial markets. Based in Newburyport, Massachusetts, UFP Technologies has cultivated a robust presence in the United States, leveraging a direct sales force and independent manufacturer representatives to market and sell its innovative solutions.
UFP Technologies, Inc. offers a diverse portfolio of products and services across various industries: